- Home
- KYN vs CNTA Comparison
KYN vs CNTA Comparison
Compare KYN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYN
- CNTA
- Stock Information
- Founded
- KYN 2004
- CNTA 2020
- Country
- KYN United States
- CNTA United Kingdom
- Employees
- KYN N/A
- CNTA N/A
- Industry
- KYN Finance/Investors Services
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- KYN Finance
- CNTA Health Care
- Exchange
- KYN Nasdaq
- CNTA Nasdaq
- Market Cap
- KYN 2.1B
- CNTA 2.3B
- IPO Year
- KYN N/A
- CNTA 2021
- Fundamental
- Price
- KYN $12.13
- CNTA $17.16
- Analyst Decision
- KYN
- CNTA Strong Buy
- Analyst Count
- KYN 0
- CNTA 7
- Target Price
- KYN N/A
- CNTA $23.71
- AVG Volume (30 Days)
- KYN 561.5K
- CNTA 705.7K
- Earning Date
- KYN 01-01-0001
- CNTA 11-12-2024
- Dividend Yield
- KYN 8.99%
- CNTA N/A
- EPS Growth
- KYN N/A
- CNTA N/A
- EPS
- KYN 0.71
- CNTA N/A
- Revenue
- KYN N/A
- CNTA $6,853,000.00
- Revenue This Year
- KYN N/A
- CNTA N/A
- Revenue Next Year
- KYN N/A
- CNTA N/A
- P/E Ratio
- KYN $13.79
- CNTA N/A
- Revenue Growth
- KYN N/A
- CNTA N/A
- 52 Week Low
- KYN $7.84
- CNTA $6.65
- 52 Week High
- KYN $9.88
- CNTA $18.97
- Technical
- Relative Strength Index (RSI)
- KYN 38.67
- CNTA 50.89
- Support Level
- KYN $11.71
- CNTA $16.02
- Resistance Level
- KYN $13.36
- CNTA $18.12
- Average True Range (ATR)
- KYN 0.32
- CNTA 1.08
- MACD
- KYN -0.18
- CNTA -0.08
- Stochastic Oscillator
- KYN 23.08
- CNTA 41.42
About KYN Kayne Anderson Energy Infrastructure Fund Inc.
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.